Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -3.09% and Operating profit at 14.41% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- PRE-TAX PROFIT(Q) At CNY -6.61 MM has Fallen at -239.17%
- NET PROFIT(Q) At CNY -6.39 MM has Fallen at -178.45%
- INVENTORY TURNOVER RATIO(HY) Lowest at 3.03%
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,652 Million (Small Cap)
21.00
NA
0.00%
-0.52
11.39%
2.35
Revenue and Profits:
Net Sales:
86 Million
(Quarterly Results - Jun 2025)
Net Profit:
113 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
121.02%
0%
121.02%
6 Months
86.8%
0%
86.8%
1 Year
172.59%
0%
172.59%
2 Years
80.84%
0%
80.84%
3 Years
40.73%
0%
40.73%
4 Years
67.27%
0%
67.27%
5 Years
55.27%
0%
55.27%
Zhejiang Yatai Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.09%
EBIT Growth (5y)
14.41%
EBIT to Interest (avg)
-1.50
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.32
Tax Ratio
1.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
1.39%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.35
EV to EBIT
-60.93
EV to EBITDA
1545.85
EV to Capital Employed
3.83
EV to Sales
6.26
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
-6.29%
ROE (Latest)
11.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
86.10
63.40
35.80%
Operating Profit (PBDIT) excl Other Income
-1.80
-0.30
-500.00%
Interest
32.20
2.50
1,188.00%
Exceptional Items
2.40
-1.40
271.43%
Consolidate Net Profit
113.00
-7.80
1,548.72%
Operating Profit Margin (Excl OI)
-121.30%
-140.10%
1.88%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 35.80% vs -34.37% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 1,548.72% vs -120.69% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
398.80
414.50
-3.79%
Operating Profit (PBDIT) excl Other Income
27.40
8.30
230.12%
Interest
30.60
47.50
-35.58%
Exceptional Items
-3.30
49.00
-106.73%
Consolidate Net Profit
34.20
-11.90
387.39%
Operating Profit Margin (Excl OI)
-24.30%
-77.40%
5.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -3.79% vs 12.61% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 387.39% vs 91.03% in Dec 2023
About Zhejiang Yatai Pharmaceutical Co., Ltd. 
Zhejiang Yatai Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






